Cargando…
Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321697/ https://www.ncbi.nlm.nih.gov/pubmed/32637035 http://dx.doi.org/10.18632/oncotarget.27403 |
| _version_ | 1783551528203714560 |
|---|---|
| author | Robb, Caroline M. Kour, Smit Contreras, Jacob I. Agarwal, Ekta Barger, Carter J. Rana, Sandeep Sonawane, Yogesh Neilsen, Beth K. Taylor, Margaret Kizhake, Smitha Thakare, Rhishikesh N. Chowdhury, Sanjib Wang, Jing Black, Jennifer D. Hollingsworth, Michael A. Brattain, Michael G. Natarajan, Amarnath |
| author_facet | Robb, Caroline M. Kour, Smit Contreras, Jacob I. Agarwal, Ekta Barger, Carter J. Rana, Sandeep Sonawane, Yogesh Neilsen, Beth K. Taylor, Margaret Kizhake, Smitha Thakare, Rhishikesh N. Chowdhury, Sanjib Wang, Jing Black, Jennifer D. Hollingsworth, Michael A. Brattain, Michael G. Natarajan, Amarnath |
| author_sort | Robb, Caroline M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7321697 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73216972020-07-06 Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy Robb, Caroline M. Kour, Smit Contreras, Jacob I. Agarwal, Ekta Barger, Carter J. Rana, Sandeep Sonawane, Yogesh Neilsen, Beth K. Taylor, Margaret Kizhake, Smitha Thakare, Rhishikesh N. Chowdhury, Sanjib Wang, Jing Black, Jennifer D. Hollingsworth, Michael A. Brattain, Michael G. Natarajan, Amarnath Oncotarget Correction Impact Journals LLC 2020-06-23 /pmc/articles/PMC7321697/ /pubmed/32637035 http://dx.doi.org/10.18632/oncotarget.27403 Text en Copyright: © 2019 Robb et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Robb, Caroline M. Kour, Smit Contreras, Jacob I. Agarwal, Ekta Barger, Carter J. Rana, Sandeep Sonawane, Yogesh Neilsen, Beth K. Taylor, Margaret Kizhake, Smitha Thakare, Rhishikesh N. Chowdhury, Sanjib Wang, Jing Black, Jennifer D. Hollingsworth, Michael A. Brattain, Michael G. Natarajan, Amarnath Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy |
| title | Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy |
| title_full | Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy |
| title_fullStr | Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy |
| title_full_unstemmed | Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy |
| title_short | Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy |
| title_sort | correction: characterization of cdk(5) inhibitor, 20-223 (aka cp668863) for colorectal cancer therapy |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321697/ https://www.ncbi.nlm.nih.gov/pubmed/32637035 http://dx.doi.org/10.18632/oncotarget.27403 |
| work_keys_str_mv | AT robbcarolinem correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT koursmit correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT contrerasjacobi correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT agarwalekta correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT bargercarterj correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT ranasandeep correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT sonawaneyogesh correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT neilsenbethk correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT taylormargaret correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT kizhakesmitha correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT thakarerhishikeshn correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT chowdhurysanjib correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT wangjing correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT blackjenniferd correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT hollingsworthmichaela correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT brattainmichaelg correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy AT natarajanamarnath correctioncharacterizationofcdk5inhibitor20223akacp668863forcolorectalcancertherapy |